ONCC Certification Test Results Are Announced

Elevating the Quality of Cancer Care Via Cross-Department Collaboration

The ESMO Precision Oncology Working Group recommendations can serve as guidance to define standards for MTBs to integrate precision oncology into practice.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD

Once-Weekly Doses of Carfilzomib Show Balanced Benefit in Real-World RRMM

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

A real-world analysis showed that 56 mg/m2 of carfilzomib once weekly offered many benefits over 56 mg/m2 twice weekly and 70 mg/m2 once weekly in myeloma.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

April 1st 2025

Active Surveillance Shows Noninferior OS vs Surgery in Esophageal Cancer

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Postoperative complications and mortality after standard or postponed surgery for esophageal cancer after active surveillance were similar in both groups.

April 5th 2025

EC Approves T-DXd Monotherapy in HR+, HER2-Low/Ultralow Breast Cancer

Postoperative complications and mortality after standard or postponed surgery for esophageal cancer after active surveillance were similar in both groups.

April 4th 2025

ESMO Develops Molecular Tumor Boards Guidelines to Standardize Practice

Results from the phase 3 DESTINY-Breast06 trial demonstrated that T-DXd monotherapy improved PFS over chemotherapy in patients with breast cancer.

Related Content

Elevating the Quality of Cancer Care Via Cross-Department Collaboration

The ESMO Precision Oncology Working Group recommendations can serve as guidance to define standards for MTBs to integrate precision oncology into practice.

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD

Once-Weekly Doses of Carfilzomib Show Balanced Benefit in Real-World RRMM

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

A real-world analysis showed that 56 mg/m2 of carfilzomib once weekly offered many benefits over 56 mg/m2 twice weekly and 70 mg/m2 once weekly in myeloma.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

April 1st 2025

Active Surveillance Shows Noninferior OS vs Surgery in Esophageal Cancer

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

April 5th 2025

EC Approves T-DXd Monotherapy in HR+, HER2-Low/Ultralow Breast Cancer

Postoperative complications and mortality after standard or postponed surgery for esophageal cancer after active surveillance were similar in both groups.

April 4th 2025